FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee

FDA's Pazdur says the time has come for an Oncologic Drugs Advisory Committee meeting devoted to issues surrounding use of progression-free survival endpoints - including clinical relevance.